Measuring Psoriasis Severity at Home
March 1st, 2024
This paper details the creation of a Psoriasis Thickness Reference Card, enabling psoriasis patients to self-assess their psoriasis plaque thickness without the need for physician assistance. Additionally, the precision of self-assessment for psoriasis redness and scaliness by employing reference images depicting various skin tones is assessed.
Our research focuses on the healthcare of patients affected with psoriasis and psoriatic arthritis. One of the questions we try to answer is how to predict psoriatic arthritis among psoriasis patients using a cost-efficient approach that is accessible to remote locations. Our protocol enables patients to measure the severity of their psoriasis lesions without the need for a physician's assistance.
They can even perform these assessments at home. The protocol will improve population-based research by expanding patient outreach and accessibility. Additionally, patient can utilize the protocol to track treatment response effectively.
To begin, write down the number 0, 3, 5, 8, 10, and 13 on any paper to make the psoriasis thickness reference card. Take a package of sticky notes. Sequentially place stacks of three, five, eight, 10, and 13 sticky notes on the boxes labeled with respective numbers, aligning the adhesive side of the sticky notes on the left side of each corresponding box.
Firmly adhere each stack to the paper. Apply a strip of tape along the right side of each stack of sticky notes. Ensure the tape adheres smoothly, creating a gentle slope between the top of the stack and the paper.
Slide a finger across the edge of the thickest psoriasis patch, noting its elevation from the surrounding skin. Similarly, slide a finger across the taped side of each stack of sticky notes to assess their thickness. Identify the stack that best matches the elevation of the thickest psoriasis patch and record the corresponding score.
There was no significant difference between patient and physician reports of desquamation, erythema, and induration by the Wilcoxon signed-rank test.
Overview
This study introduces a Psoriasis Thickness Reference Card that allows patients to self-assess their psoriasis plaque thickness independently. It also evaluates the accuracy of self-assessing psoriasis redness and scaliness using reference images of various skin tones.
Key Study Components
Area of Science
- Psoriasis management
- Patient self-assessment
- Healthcare accessibility
Background
- Psoriasis is a chronic skin condition affecting many individuals.
- Patients often require assistance from healthcare providers for assessment.
- Self-assessment tools can enhance patient engagement and monitoring.
- Utilizing reference images can improve assessment accuracy across diverse skin tones.
Purpose of Study
- To develop a tool for patients to measure psoriasis severity independently.
- To assess the effectiveness of self-assessment methods for psoriasis characteristics.
- To enhance research accessibility for remote patient populations.
Methods Used
- Creation of a reference card for psoriasis plaque thickness.
- Evaluation of self-assessment accuracy using reference images.
- Implementation of a protocol for home assessments.
- Analysis of treatment response tracking by patients.
Main Results
- Patients can effectively measure plaque thickness without physician assistance.
- Self-assessment methods show promise in tracking psoriasis characteristics.
- Reference images improve assessment accuracy for diverse skin tones.
- The protocol enhances patient outreach and research participation.
Conclusions
- The Psoriasis Thickness Reference Card is a valuable tool for patient self-assessment.
- Improved accessibility can lead to better management of psoriasis.
- Future research can benefit from patient-driven data collection.
Frequently Asked Questions
Executive Industry Relevance
Remote, patient-driven quantification of psoriasis severity addresses a critical gap in early detection and monitoring of psoriatic arthritis risk among cutaneous-only psoriasis patients. Enabling self-assessment of induration, erythema, and desquamation supports scalable, population-level screening and longitudinal data collection. This approach enhances predictive confidence for translational research and portfolio triage in dermatological and immunology pipelines.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables hypothesis-driven investigation of psoriasis severity metrics as translational biomarkers for psoriatic arthritis risk.
- Supports biological de-risking by standardizing patient-reported severity data across diverse populations.
- Facilitates predictive confidence in linking cutaneous metrics to systemic disease progression.
Screening & Assay Development
- Provides validated, quantitative patient-reported outcomes for use in digital screening tools.
- Standardizes severity assessment, improving reproducibility and comparability across studies.
- Enables scalable, remote data collection for high-throughput screening and cohort enrichment.
Translational & Preclinical Research
- Aligns patient-reported severity metrics with disease-relevant endpoints for translational studies.
- Supports continuity from discovery through preclinical validation by enabling longitudinal tracking of treatment response.
- Reduces risk of late-stage attrition by integrating real-world, patient-driven data into early research.
Pipeline & Workflow Integration
This patient self-assessment protocol integrates into the discovery-to-preclinical continuum by enabling remote, quantitative phenotyping and risk stratification.
- Discovery Biology: Supports hypothesis testing on the predictive value of cutaneous severity metrics for systemic disease risk.
- Screening: Delivers standardized, reproducible patient-reported data for digital screening and cohort selection.
- Analytics: Provides quantitative outputs for statistical comparison between patient and physician assessments.
- Translational Research: Bridges patient-reported outcomes with clinical endpoints for biomarker alignment.
- Enterprise Reuse: Offers a scalable, reusable protocol for remote phenotyping in dermatology and immunology research portfolios.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and target validation for psoriatic arthritis risk assessment.
- Operational Value: Standardizes and scales severity assessment across remote and diverse patient populations.
- Strategic Value: Enables data-driven go/no-go decisions and reduces late-stage biological risk.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of dermatology and immunology assets.
Implementation Considerations
- Requires patient education for accurate self-assessment using reference images and tactile cards.
- Minimal instrumentation needs, leveraging simple materials for the reference card.
- Standardization protocols must be established for cross-study comparability.
- Adaptation may be needed for different skin types and lesion presentations.
- Dependent on patient engagement and adherence for reliable longitudinal data.
